EWM
BCRX icon

Empirical Wealth Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Empirical Wealth Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$417K Sell
41,730
-2,507
-6% -$22.7K 0.01% 752
2026
Q1 		$421K Buy
44,237
+11,327
+34% +$88K 0.01% 646
2025
Q4 		$257K Buy
32,910
+8,474
+35% +$61.3K ﹤0.01% 753
2025
Q3 		$185K Buy
+24,436
New +$203K ﹤0.01% 770

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Empirical Wealth Management's BCRX Position: Q2 2026 in Review

Empirical Wealth Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 5.7% in Q2 2026, selling an estimated $22.7K and leaving 41,730 shares worth $417K. The position accounts for 0.01% of the portfolio, ranked #752.

Empirical Wealth Management first reported a position in BCRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $421K in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Empirical Wealth Management held 41,730 shares of BioCryst Pharmaceuticals worth $417K as of Q2 2026.
  • Empirical Wealth Management sold 2,507 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $22.7K.
  • BioCryst Pharmaceuticals made up 0.01% of Empirical Wealth Management's portfolio in Q2 2026, its #752 holding.
  • Empirical Wealth Management first reported a position in BioCryst Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Empirical Wealth Management's BioCryst Pharmaceuticals position peaked at $421K in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Empirical Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.